President Trump Is Considering Rescheduling Cannabis. Is Now the Time to Load Up on Pot Stocks?

Renewed speculation regarding the potential U.S. government rescheduling of cannabis from Schedule I to a lower classification, such as Schedule III, has fueled a significant rally in cannabis stocks. This reclassification, reportedly under consideration by President Trump, would primarily benefit U.S. multi-state operators by eliminating the onerous Section 280E tax code, enabling them to deduct ordinary business expenses and substantially reduce tax liabilities, with companies like Curaleaf estimating annual savings of $150 million. While this offers a material near-term financial boost for MSOs, the article cautions that rescheduling is not legalization, and the broader cannabis market remains speculative and high-risk despite recent investor enthusiasm.

Analysis

Renewed political consideration for rescheduling cannabis from Schedule I to a lower classification, such as Schedule III, represents a significant potential catalyst for the U.S. cannabis sector. The primary and most immediate impact would be the elimination of Section 280E of the tax code for state-legal operators, a provision that currently prevents them from deducting standard business expenses. This change would materially improve the financial viability of U.S. multi-state operators (MSOs). For instance, Curaleaf Holdings (CURLF) estimates it could realize approximately $150 million in annual tax savings, a substantial figure given its $114 million net loss and $68 million tax provision in the first half of the year, despite an 8% year-over-year revenue decline. The market's reaction has been broad, with investor enthusiasm lifting Canadian licensed producers like Tilray Brands (TLRY), which saw its stock surge by 58% in five trading days. However, this rally appears sentiment-driven, as rescheduling would not grant Canadian firms access to the U.S. market. This highlights a critical distinction for investors: the direct beneficiaries are U.S.-domiciled MSOs, while the positive momentum for non-U.S. players is speculative and not tied to a direct fundamental improvement from this specific regulatory shift.

Key Decisions for Investors

• Investors should differentiate between U.S. multi-state operators like Curaleaf, which would receive direct and material financial benefits from tax relief under rescheduling, and Canadian producers like Tilray, whose recent stock appreciation is primarily sentiment-driven and lacks a direct fundamental catalyst from this specific U.S. policy change.
• While the potential elimination of the 280E tax provision is a significant positive for MSOs, it is crucial to scrutinize the underlying operational performance, such as Curaleaf's reported 8% revenue decline, as tax savings alone do not resolve core challenges with growth and profitability.
• Given that rescheduling is not guaranteed and is distinct from full legalization, positions in the cannabis sector should be managed with an understanding of high regulatory risk and potential for volatility; the current rally is based on a potential development, not a finalized reform.